DVAX.US stock price is influenced by various factors. Product Pipeline Progress: Positive clinical trial results and regulatory approvals for Dynavax's vaccines, particularly Heplisav-B, typically boost the stock price.

Competition: Developments in the hepatitis B vaccine market and emergence of competing products can negatively impact Dynavax's market share and stock price.

Market Sentiment: Overall market conditions and investor sentiment towards biotechnology stocks can affect DVAX.US, irrespective of company-specific news.

Financial Performance: Dynavax's revenue, earnings, and profitability directly influence investor confidence and stock valuation.

Partnerships and Collaborations: Strategic alliances with other companies for vaccine development or commercialization can positively impact the stock.

Regulatory Environment: Changes in regulations related to vaccines or healthcare policies can affect Dynavax's business operations and stock price.

Manufacturing and Supply Chain: Disruptions in manufacturing or supply chain issues can negatively affect vaccine production and impact the stock.

Economic Conditions: Economic downturns can affect healthcare spending and potentially impact demand for vaccines, influencing DVAX.US.

Company News and Announcements: Major announcements regarding product development, partnerships, or financial results can trigger significant stock price movements.